NL-OMON36461已完成不适用
A rising multiple dose study to investigate the safety, tolerability, pharmacokinetics and pharmacodynamics of orally administered SCH 900389 in healthy females (P07036) - P07036
Schering-Plough0 个研究点目标入组 52 人开始时间: 待定最近更新:
适应症
试验速览
- 阶段
- 不适用
- 状态
- 已完成
- 发起方
- 入组人数
- 52
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- 18 至 99（—）
入选标准
- •Healthy female subjects
排除标准
- •Clinical significant abnormalities at screening
研究者
相似试验
已完成
1 期
K757 and K833 multiple-dose study in healthy subjectsHealthy subjectsISRCTN13328584Kallyope (United States)36
已完成
1 期
Study to investigate the safety of ENX-101 and how well it works in healthy volunteers.Epilepsy, spasticity and anxiety disordersISRCTN18262237Engrail Therapeutics, Inc.53
进行中（未招募）
1 期
A multiple ascending dose study to evaluate the safety, tolerability and effect on tumor response of the mTOR inhibitor (RAD001) in combination with the IGF-1R antagonist (R1507) in patients with advanced solid tumorsPIb: solid malignancy that is metastatic or unresectable PII: C 1: Advanced metastatic renal cell carcinoma C 2: Advanced low- to intermediate grade metastatic or unresectable locoregional pancreatic neuroendocrine tumors + carcinoid tumorsMedDRA version: 9.1Level: LLTClassification code 10050076Term: Metastatic renal carcinomaMedDRA version: 9.1Level: LLTClassification code 10065147Term: Malignant solid tumorMedDRA version: 9.1Level: LLTClassification code 10052399Term: Neuroendocrine tumourMedDRA version: 9.1Level: LLTClassification code 10026664Term: Malignant pancreatic islet neoplasmEUCTR2008-005806-38-FRF.Hoffmann-La Roche Ltd.134
已完成
1 期
A Study of LY3437943 in Japanese Participants With Type 2 Diabetes Mellitus (T2DM)Type 2 Diabetes MellitusJPRN-jRCT2051210029Wakayama Naohiko66
未知
1 期
Multiple-Dose, Dose Escalation Study to Evaluate Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of LY2439821 in Japanese Patients with Rheumatoid Arthritis on Concomitant Methotrexate TreatmentRheumatoid ArthritisJPRN-jRCT2080221108Eli Lilly Japan K.K.